Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...

Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.

Eli Lilly and Company (NYSE:LLY), a leading global pharmaceutical firm, finds itself at a pivotal juncture as it navigates a ...

Lilly's (LLY) products were taken off the shortage list in October. Some of Novo Nordisk's (NVO) semaglutide formulations remain on the list. Lilly (LLY) markets tirzepatide for diabetes as ...

Lilly is providing the low-dose vials solely through LillyDirect, in effect steering patients towards its products. Additionally, while patients can access medicines through LillyDirect prescribed ...

Leerink Partners analyst David Risinger maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on January 24 and set a price ...

"2024 was a pivotal and highly successful year for Lilly, and we expect to continue ... intense competition affecting the company's products, pipeline, or industry; market uptake of launched ...

Websites selling compounded versions of popular weight-loss drugs from Novo Nordisk and Eli Lilly to U.S. consumers often do ...

In a report released today, Terence Flynn from Morgan Stanley reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report), with a ...